- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | MICROBA LIFE SCIENCES LIMITED: Cleansing Notice | 2 | ASX | ||
| Mi | MICROBA LIFE SCIENCES LIMITED: Application for quotation of securities - MAP | - | ASX | ||
| MICROBA LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
| Di | MICROBA LIFE SCIENCES LIMITED: Letter to Shareholders, Notice of AGM & Proxy Form | - | ASX | ||
| Di | MICROBA LIFE SCIENCES LIMITED: Final Director's Interest Notice - Ian Frazer | 2 | ASX | ||
| Di | MICROBA LIFE SCIENCES LIMITED: Final Director's Interest Notice - Gene Tyson | 1 | ASX | ||
| 22.10. | MICROBA LIFE SCIENCES LIMITED: Notification of cessation of securities - MAP | - | ASX | ||
| 21.10. | MICROBA LIFE SCIENCES LIMITED: GSS: Update on Commercial Terms for Proposed Merger with MAP | 2 | ASX | ||
| 20.10. | MICROBA LIFE SCIENCES LIMITED: Proposed issue of securities - MAP | 1 | ASX | ||
| 20.10. | MICROBA LIFE SCIENCES LIMITED: Proposed issue of securities - MAP | 3 | ASX | ||
| 20.10. | MICROBA LIFE SCIENCES LIMITED: Q1 FY27 Quarterly Activities Report & Appendix 4C | 1 | ASX | ||
| 20.10. | MICROBA LIFE SCIENCES LIMITED: Microba secures $2m placement and increases cost reductions | 1 | ASX | ||
| 14.10. | MICROBA LIFE SCIENCES LIMITED: Date of AGM and closing date for Director Nominations | 1 | ASX | ||
| 13.10. | MICROBA LIFE SCIENCES LIMITED: Notification of cessation of securities - MAP | - | ASX | ||
| 07.10. | MICROBA LIFE SCIENCES LIMITED: Microba launches GI Navigator in Australia and the UK | - | ASX | ||
| 30.09. | MICROBA LIFE SCIENCES LIMITED: Change in substantial holding | - | ASX | ||
| 25.09. | MICROBA LIFE SCIENCES LIMITED: Appointment of Interim Chief Executive Officer | 1 | ASX | ||
| 22.09. | Health Check: Microba and Genetic Signatures have urge to merge, but is it game over? | 2 | Stockhead | ||
| 22.09. | Genetic Signatures and Microba Life Sciences Set Commercial Terms for Merger | 2 | smallcaps.com.au | ||
| 22.09. | MICROBA LIFE SCIENCES LIMITED: GSS and MAP agree to Commercial Terms for Merger | 1 | ASX | ||
| 31.08. | MICROBA LIFE SCIENCES LIMITED: 2026 Annual Report & Appendix 4E | 1 | ASX |
1 2 3 Weiter >>
60 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,090 | +0,09 % | Qiagen zieht an, Siemens Energy schmiert ab: DAX-Ausblick | Der DAX ist in der vergangenen Woche wieder deutlich zurückgefallen. Unter dem Strich büßte das größte deutsche Börsenbarometer 440 Punkte ein und schloss -1,72% tiefer mit 25.181 Punkten. Die höchsten... ► Artikel lesen | |
| COGENT BIOSCIENCES | 31,020 | 0,00 % | Stifel bekräftigt Kaufempfehlung für Cogent Biosciences nach ESMO-Daten | ||
| ENLIVEN THERAPEUTICS | 44,250 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year | Accomplished biopharmaceutical executive with extensive experience in corporate strategy, finance and commercial readiness
Enliven continues preparation for late-stage... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 18,155 | -0,14 % | Mineralys Therapeutics, Inc. - 8-K, Current Report | ||
| KYMERA THERAPEUTICS | 126,72 | +0,07 % | Oppenheimer raises Kymera Therapeutics price target on drug data | ||
| TANGO THERAPEUTICS | 22,710 | 0,00 % | Tango Therapeutics (TNGX) vs. CRSP and SMMT: Can Vopimetostat Turn Promising Cancer Data Into an 89% Upside? | ||
| BAMBUSA THERAPEUTICS | 14,900 | -0,60 % | Bambusa Therapeutics, Inc.: Bambusa Therapeutics Announces Pricing of Upsized Initial Public Offering | BOSTON, Oct. 29, 2026 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Nasdaq: BBTX) ("Bambusa Therapeutics" or " Bambusa"), a clinical-stage biopharmaceutical company developing next-generation, long-acting... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,025 | -0,12 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| SUMMIT THERAPEUTICS | 16,030 | 0,00 % | Summit Therapeutics: Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China | First Regimen to Achieve a Statistically Significant and Clinically Meaningful Overall Survival Benefit over an Anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in... ► Artikel lesen | |
| VOR BIOPHARMA | 19,680 | 0,00 % | Vor Bio Down on Q3 Results | ||
| KINIKSA PHARMACEUTICALS | 92,10 | -0,15 % | Goldman Sachs raises Kiniksa stock price target on strong Arcalyst sales | ||
| PRIME MEDICINE | 4,720 | 0,00 % | Prime Medicine, Inc.: Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease | -- Global, first-in-human study underway designed to evaluate safety, tolerability, and initial clinical efficacy of PM577a -- -- PM577a is designed as a one-time therapy to correct the H1069Q mutation... ► Artikel lesen | |
| ERASCA | 14,330 | -0,14 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| ABSCI | 11,125 | -0,04 % | Jefferies nimmt Absci mit "Buy" auf - Potenzial bei Wirkstoff gegen Haarausfall im Fokus | ||
| NURIX THERAPEUTICS | 26,780 | -0,07 % | Nurix Therapeutics Swings To Profit In Q3 On Roche Licensing Revenue | SOUTH SAN FRANCISCO (dpa-AFX) - Nurix Therapeutics, Inc. (NRIX), clinical-stage biopharmaceutical company, reported a swing to profit in the third quarter from a loss in the year-ago period... ► Artikel lesen |
MICROBA LIFE SCIENCES LIMITED gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -8,33 % bei einem Aktienkurs von 0,017 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MICROBA LIFE SCIENCES LIMITED finden Sie auf Wallstreet Online.